ClinicalTrials.gg
Not yet recruitingNCT07754799Updated Aug 26, 2026

A Randomized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid Leukemia

A Phase 2 interventional study of Daunorubicin and Cytarabine in Acute Myeloid Leukemia (AML), sponsored by Institute of Hematology & Blood Diseases Hospital, China. Not yet recruiting. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
320
Allocation
Randomized
Ages
14 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing daunorubicin in Leukemia, Myeloid, Acute — 11 open to participants now, 16 under way, 4 of them phase 3. Daunorubicin · Leukemia, Myeloid, Acute.

Planned enrollment
15th of 48
320 · median 111
Started
2026
with 1 other
Phase 2
16 of 50
5 open now
Primary completion
2029-09
later than 13 of 15 live
Registered
49th of 50
by date
Lead sponsor
2 of 50
Institute of Hematology & Blood Diseases Hospital, China

Among the 50 studies testing daunorubicin in Leukemia, Myeloid, Acute, this one is the 15th largest by planned enrollment of the 48 interventional ones that give a count, is one of 2 that started in 2026, is one of 16 in phase 2, reaches primary completion later than 13 of the 15 other live ones, and was the 49th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

11 of the 50 studies testing daunorubicin in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About daunorubicin

Daunorubicin: first FDA approval 1979 (CERUBIDINE), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 14 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing daunorubicin in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This randomized, open label, multi arm phase II trial will evaluate the efficacy and safety of venetoclax based induction regimens of varying intensity (VA, VAM, or 2+5+V) versus standard 3+7 in fit patients aged ≥14 years with newly diagnosed AML. The trial is designed to select the optimal regimen as the experimental arm for a subsequent phase III randomized controlled trial.

A total of 320 patients will be enrolled in this study,and segregated into four groups with 80 in each group. Patients who achieve CR/CRi/CRh after using different induction regimens will receive the same consolidation. Allogeneic hematopoietic stem cell transplantation is recommended for patients in the high-risk group or those with persist MRD positivity. After completion of the treatment phase, patients entered the follow-up period.

03

Conditions studied

  • Acute Myeloid Leukemia (AML)
04

Who can participate

Ages eligible
14 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of AML per WHO (2022) or ICC criteria, and MDS/AML as defined by ICC (with bone marrow blast percentage of 10%-20%).
  • Age ≥14 years, male or female.
  • (ECOG) performance status of 0 to 2.
  • Judged by the investigator to be suitable for intensive induction chemotherapy and expected to tolerate the treatment intensity specified in the protocol.
  • Meet the following laboratory test requirements (assessed within 7 days prior to treatment):

    1. Total ≤1.5 × (ULN) for the same age group;
    2. and ALT ≤2.5 × ULN for the same age group;
    3. Serum creatinine \<2 × ULN for the same age group;
    4. Cardiac enzymes \<2 × ULN for the same age group;
    5. Cardiac determined by echocardiography (ECHO) within the normal range.
  • Written must be signed before any study specific procedures are initiated, by the patient themselves or by their immediate family members. If, in consideration of the patient's medical condition, signing by the patient themselves would be detrimental to their treatment, the informed consent may be signed by the legally authorized representative or the patient's immediate family members.

Exclusion criteria

Exclusion Criteria:

  • Acute promyelocytic leukemia with PML-RARA fusion gene.
  • Acute myeloid leukemia with RUNX1-RUNX1T1 or CBFB-MYH11 fusion gene.
  • Acute myeloid leukemia with BCR-ABL fusion gene.
  • Presence of FLT3 mutation (these patients are recommended to be enrolled in clinical trials of FLT3 inhibitors).
  • Patients who have previously received induction chemotherapy (however, cytoreductive therapy such as hydroxyurea is permitted).
  • Concurrent of other organs that requires treatment.
  • Active cardiac disease, defined as one or more of the following:

    1. History of uncontrolled or symptomatic angina pectoris;
    2. Myocardial infarction within 6 months prior to study enrollment;
    3. History of arrhythmia requiring medication or with symptoms;
    4. Uncontrolled or symptomatic congestive heart failure (> class 2).
  • Serious infectious diseases (e.g., active tuberculosis, pulmonary aspergillosis).
  • Patients deemed unsuitable for enrollment by the investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
320 participants (estimated)

Study arms

  • Active comparator
    3+7

    Drug: daunorubicin daunorubicin: 60 mg/m2, administered by intravenous drip (ivgtt) on days 1-3, Drug: Cytarabine Cytarabine: 100 mg/m2, administered by intravenous drip (ivgtt) on days 1-7,

    Drug: Daunorubicin · Drug: Cytarabine

  • Experimental
    VAM

    Drug: Liposome Mitoxantrone Liposome Mitoxantrone: 24 mg/m², administered by intravenous drip (ivgtt) on day 1, every 4 weeks Drug: Venetoclax Venetoclax: 100 mg on day 1, 200 mg on day 2, and 400 mg on days 3-14, administered orally (po), every 4 weeks Drug: Azacitidine Azacitidine: 75 mg/m², administered subcutaneously (sc) on days 1-7,

    Drug: Liposome Mitoxantrone · Drug: Venetoclax · Drug: Azacitidine

  • Experimental
    VA

    Drug: Venetoclax Venetoclax: 100 mg on day 1, 200 mg on day 2, and 400 mg on days 3-21, administered orally (po). Bone marrow examination is performed on day 21. If blasts \>5%, then venetoclax 400 mg is continued on days 21-28. Drug: Azacitidine Azacitidine: 75 mg/m², administered subcutaneously (sc) on days 1-7,

    Drug: Azacitidine · Drug: Venetoclax

  • Experimental
    2+5+V

    Drug: daunorubicin daunorubicin: 60 mg/m2, administered by intravenous drip (ivgtt) on days 1-2, every 4 weeks Drug: Cytarabine Cytarabine: 100 mg/m2, administered by intravenous drip (ivgtt) on days 1-5, every 4 weeks Drug: Venetoclax Venetoclax: 100 mg on day 3, 200 mg on day 4, and 400 mg on days 5-11, administered orally (po)

    Drug: Daunorubicin · Drug: Cytarabine · Drug: Venetoclax

Interventions

  • daunorubicin: 60 mg/m2, administered by intravenous drip (ivgtt) on days 1-3,

  • Cytarabine: 100 mg/m2, administered by intravenous drip (ivgtt) on days 1-7,

  • DrugLiposome Mitoxantrone

    Liposome Mitoxantrone: 24 mg/m², administered by intravenous drip (ivgtt) on day 1,

  • Venetoclax: 100 mg on day 1, 200 mg on day 2, and 400 mg on days 3-14, administered orally (po),

  • Azacitidine: 75 mg/m², administered subcutaneously (sc) on days 1-7,

  • Venetoclax: 100 mg on day 1, 200 mg on day 2, and 400 mg on days 3-21, administered orally (po). Bone marrow examination is performed on day 21. If blasts \>5%, then venetoclax 400 mg is continued on days 21-28.

  • daunorubicin: 60 mg/m2, administered by intravenous drip (ivgtt) on days 1-2,

  • Cytarabine: 100 mg/m2, administered by intravenous drip (ivgtt) on days 1-5,

  • Venetoclax: 100 mg on day 3, 200 mg on day 4, and 400 mg on days 5-11, administered orally (po),

06

What researchers measure

Primary outcomes

  1. Event-free survival (EFS)

    It is defined as the time from the start of randomization to the occurrence of induction failure or disease progression or death from any cause (whichever occurs first).

    Time frame: up to 3 years

Secondary outcomes

  1. 30-day postinduction mortality

    It is defined as death from any cause within 30 days after the start of induction.

    Time frame: up to 30 days

  2. 60-day postinduction mortality

    It is defined as death from any cause within 60 days after the start of induction.

    Time frame: Up to 60 days

  3. Composite complete remission (CRc) rate

    Proportion of patients with complete remission (CR), complete remission with partial hematologic recovery (CRh) or complete remission with incomplete hematologic recovery (CRi).

    Time frame: Up to eight weeks

  4. Measurable Residual Disease (MRD) negative rate by flow cytometry

    Among those who have achieved CR/CRh/CRi after induction, proportion of patients who is MRD-negative by flow cytometry.

    Time frame: Up to eight weeks

  5. Measurable Residual Disease (MRD) negative rate by molecular testing

    Among those who have achieved CR/CRh/CRi after induction, proportion of patients who is MRD-negative by molecular testing.

    Time frame: Up to approximately eight weeks

  6. Relapse-free Survival (RFS)

    It is defined as the time from the start of achieving remission to disease progression, death from any cause or the last follow-up.

    Time frame: Up to 3 years

  7. Overall survival (OS)

    It is defined as the time from the start of randomization to the death from any cause.

    Time frame: Up to 3 years

  8. Cumulative incidence of relapse (CIR)

    It is defined as the time from the start of achieving remission to hematologic relapse.

    Time frame: Up to 3 years

  9. Incidence of treatment related adverse events

    The safety of the drug was evaluated by NCI-CTC AE 5.0 standard which including hematologic and non-hematologic toxicity.

    Time frame: From day 1 of treatment to 28 days after the last dose

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2029, 36 months later.

Of 386 non-industry phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 108. This study's planned 36 months is below that.

Counting every sponsor, half of 443 studies reached it within 60 months; a quarter within 38 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2026
First posted
Aug 10, 2026
StartEst.
Sep 30, 2026
Primary completionEst.
Sep 30, 2029
CompletionEst.
Sep 30, 2029
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07754799
Responsible party
Sponsor
First posted
Aug 10, 2026
Start date
Sep 30, 2026 (estimated)
Primary completion
Sep 30, 2029 (estimated)
Completion
Sep 30, 2029 (estimated)
Last update
Aug 26, 2026

Study contacts

Hui Wei, MD
Contact
weihui@ihcams.ac.cn
022-23608456
Miao Yang, MD
Contact
yangmiao@ihcams.ac.cn
022-23608341

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Daunorubicin · Cytarabine · Venetoclax

Start the discussion